Evidence regarding the role of ADAM10 inhibitors in RA and SLE indicates that it may be a useful therapeutic target and also provide a personalized approach for predicting autoimmune disease patients’ responsiveness to biologic therapies [27]. The gene discussed is ADAM10; the disease is systemic lupus erythematosus.